January 17, 2025

FDA Approves Datopotamab Deruxtecan-dlnk for Advanced HR-Positive, HER2-Negative Breast Cancer

Today, the FDA approved a TROP-2–directed antibody and topoisomerase inhibitor conjugate for adult patients with unresectable or metastatic hormone receptor (HR)-positive, HER2-negative breast cancer ...

The ASCO Post

January 17, 2025

FDA Chief Warns of Online Drug Risks

Outgoing FDA Commissioner raises concerns about safety of online-purchased compounded weight loss meds, highlighting challenges faced by the FDA, amidst contrasting views from nominee for Health and Human Services Secretary.

Reuters

January 17, 2025

Trial: High-Dose Semaglutide Cuts Weight 20.7%

Novo Nordisk's high-dose semaglutide trial demonstrates a 20.7% weight reduction in overweight patients with obesity, promising new advancements in the treatment of obesity and diabetes.

Reuters

January 17, 2025

Fulvestrant vs Anastrozole in Endocrine Therapy–Naive, HR-Positive, HER2-Negative Advanced Breast Cancer

The final overall survival analysis of the phase III FALCON trial was recently reported.

The ASCO Post

January 17, 2025

Patient Care Declines After PE Acquisition

A recent study reveals that patient-reported care experience declined significantly at hospitals acquired by private equity firms, highlighting the potential impact of private equity acquisitions on patient care.

Conexiant

January 17, 2025

FDA Approves Sotorasib With Panitumumab for KRAS G12C–Mutated Colorectal Cancer

On January 16, the FDA approved a KRAS G12C inhibitor in combination with a monoclonal antibody for adult patients with KRAS G12C–mutated metastatic colorectal cancer, as determined by an FDA-approved...

The ASCO Post

January 17, 2025

FDA Approves KRAS Combo for CRC

The approval is based on results from the CodeBreaK 300 clinical trial, a randomized, open-label study that evaluated the safety and efficacy of combining sotorasib with panitumumab.

Conexiant

January 17, 2025

FDA Approves New Drug for Advanced Breast Cancer

Median progression-free survival was 6.9 months in the Datroway group versus 4.9 months in the chemotherapy group.

Conexiant

January 17, 2025

Predictive Model for Difficult Psoriatic Arthritis Treatment

"According to the predictive model, the proposed D2T PsA definition identified a small subset of patients with increased treatment difficulty. These findings highlight the need for refining the criteria to better define D2T PsA patients."

Conexiant